Cetuximab

Cetuximab is a monoclonal antibody that specifically blocks the EGFR. The efficacy of cetuximab in combination with CPT-11 or alone was evaluated in a randomised trial in metastatic colorectal cancer refractory to treatment with CPT-11. Three hundred and twenty-nine patients whose disease had progressed during or within three months after treatment with a CPT-11-based regimen were randomly assigned to receive either cetuximab and CPT-11 (at the same dose and schedule as in a pre-study regimen) or cetuximab monotherapy. The rate of response in the combination therapy was significantly higher than that in the monotherapy (22.9% vs. 10.8%, p=0.007). The median time to progression was significantly greater in the combination therapy (4.1 vs. 1.5 months, p<0.001). The median survival time was 8.6 months for the combination-therapy and 6.9 months for the monotherapy (p=0.48). Toxic effects were more frequent in the combination therapy group, but their severity and incidence were similar to those that would be expected with CPT-11 alone. Cetuximab has clinically significant activity when given alone or in combination with CPT-11 in patients with CPT-11-refractory colorectal cancer [31].

Was this article helpful?

0 0
Dealing With Erectile Dysfunction

Dealing With Erectile Dysfunction

Whether you call it erectile dysfunction, ED, impotence, or any number of slang terms, erection problems are something many men have to face during the course of their lifetimes.

Get My Free Ebook


Post a comment